Feature
August 23, 2012 — Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, finds that the 12-month post-hospital acute coronary syndrome market will initially contract from just under $2 billion in 2011 to about $1.6 billion in 2013, mainly as a result of the U.S. genericization of clopidogrel (Bristol-Myers Squibb/Sanofi’s Plavix) in 2012. Decision Resources forecasts that the post-hospital acute coronary syndrome antiplatelet/anticoagulant market will then expand to almost $2.7 billion in 2021, owing largely to uptake of oral agents with novel modes of action, such as AstraZeneca’s ticagrelor (Brilinta) and the CETP inhibitors, Merck’s anacetrapib and Eli Lilly’s evacetrapib.
August 23, 2012
Technology
Philips Healthcare and Corindus Vascular Robotics announced a distribution agreement for Corindus’ CorPath 200 System. The system was recently cleared by the U.S. Food and Drug Administration (FDA) and is the world's first robotic-assisted system for the minimally invasive as percutaneous coronary intervention (PCI) of obstructed coronary arteries.
August 23, 2012
News
August 22, 2012 — Authors of an article in the Journal of Endovascular Therapy have evaluated the effectiveness of endovascular brachytherapy using liquid beta-emitting rhenium-188 delivered in an angioplasty balloon, an improvement over earlier delivery methods.
August 22, 2012Sponsored Content
Feature | Information Technology
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
March 21, 2024
Feature | Dave Fornell
Comedian Rosie O'Donnell’s heart attack last week is helping increase public education about how women’s myocardial infarction (MI) symptoms differ from men's. She posted a blog on Monday recounting her ordeal and called for women to be more vigilant in knowing the symptoms.
August 22, 2012News
August 21, 2012 — Zoll Medical Corp. entered into an agreement to license Inovise Medical Inc.’s ambulatory Audicor technology as part of the advanced patient diagnostics in the LifeVest Wearable Defibrillator.
August 21, 2012Technology
August 21, 2012 — The U.S. Food and Drug Administration (FDA) granted marketing approval for cfrQuant, coronary flow reserve (CFR) quantification software from the University of Texas Health Science Center at Houston (UTHealth).
August 21, 2012Sponsored Content
Feature | Cardiac Imaging
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
March 05, 2024
News
August 20, 2012 — Positron Corp. announced the use of its Attrius system at Caring Heart and Brain Imaging Inc. of Manasquan, N.J., which now offers amyvid positron emission tomography (PET) scans to identify the presence of plaque in the brain.
August 20, 2012
News
August 20, 2012 — Abbott today announced that the Xience Xpedition everolimus-eluting coronary stent system received CE mark in Europe for the treatment of coronary artery disease (CAD), and the company will immediately launch the product in CE-mark countries.
August 20, 2012
Feature
August 20, 2012 — The Baylor Heart Hospital in Plano, Texas, recently became the first hospital in the world to merge two highly advanced technologies for atrial fibrillation (AF) therapy.
August 20, 2012Sponsored Content
Blog
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 11, 2023
News
August 17, 2012 —Xeridiem, a vertically integrated OEM that designs, develops and manufactures complex single-use medical devices, announced it will provide LoneStar Heart Inc. with design and development services for the minimally invasive delivery system for Algisyl-LVR, an implantable biopolymer for the treatment of dilated cardiomyopathy.
August 17, 2012
Technology
August 17, 2012 — Jarvik Heart Inc., a privately held company that develops and manufactures cardiac assist devices, announced U.S. Food and Drug Administration (FDA) approval of its pivotal trial for evaluation of the Jarvik 2000 heart for destination therapy (DT), named RELIVE (Randomized Evaluation of Long-term Intraventricular VAD [ventricular assist device] Effectiveness).
August 17, 2012
Technology
August 17, 2012 — Siemens Healthcare announced an agreement to enhance the syngo Workflow radiology information system (RIS) by incorporating eXposure, a comprehensive radiation dose management and reporting solution from Toronto-based Radimetrics.
August 17, 2012Sponsored Content
Case Study | Hemodynamic Monitoring Systems
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
November 14, 2023
News
August 15, 2012 — Sound Interventions Inc. has released three-month data from the company's first-in-human clinical study (SOUND-ITV) to treat resistant hypertension through the use of catheter-based ultrasound.
August 15, 2012
News
August 15, 2012 — Previously unreleased three-year data from the Zilver PTX randomized controlled trial of paclitaxel-eluting stents for femoropopliteal disease indicate that Cook Medical’s paclitaxel-eluting peripheral vascular stent demonstrated 83 percent freedom from TLR at 36 months in the PTX group, compared to 70.2 percent for patients treated with optimal percutaneous transluminal angioplasty and bare metal stents in the 479-patient study.
August 15, 2012
Feature | Dave Fornell
Due to the increasing number of transcatheter aortic valve replacements (TAVR) and endovascular aneurysm repair (EVAR), a new startup company has developed a transfemoral combined access and closure system to accomodate these larger sized percutaneous devices and arteriotomies.
August 15, 2012© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now